Streetbeat News

HRMY

Harmony Biosciences Holdings, Inc.

https://www.harmonybiosciences.com

Industry

Biotechnology

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders in the United States. Its product, WAKIX is a medication for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is based in Plymouth Meeting, Pennsylvania.

Open

34.52

Mkt cap

2B

Volume

220K

High

35.37

P/E Ratio

16.50

52-wk high

41.61

Low

34.28

Div yield

N/A

52-wk low

22.89

Needham analyst Ami Fadia maintains a Buy rating on Harmony Biosciences (NASDAQ:HRMY) but lowers the price target from $53 to $50.

Portfolio Pulse from Benzinga Newsdesk

February 23, 2024 | 10:44 am

Analyst ratings for Harmony Biosciences (NASDAQ:HRMY) show mixed sentiments with a recent shift towards bullishness. The average 12-month price target has increased by 31.9% to $38.25. Analysts from Needham, Mizuho, Goldman Sachs, and B of A Securities have updated their ratings and price targets, reflecting changes in market conditions and company performance. Harmony Biosciences, a commercial-stage pharmaceutical company, has shown remarkable financial health with significant revenue growth, high net margin, and effective debt management.

Portfolio Pulse from Benzinga Insights

February 22, 2024 | 4:00 pm

Needham analyst Ami Fadia reiterated a Buy rating on Harmony Biosciences (NASDAQ:HRMY) and maintained a $53 price target.

Portfolio Pulse from Benzinga Newsdesk

February 22, 2024 | 1:47 pm

Harmony Biosciences (NASDAQ:HRMY) reported Q4 2023 adjusted EPS of $0.73, surpassing the $0.48 estimate, marking a 52.08% beat but a 27.72% decrease from last year's $1.01. Sales reached $168.41M, slightly missing the $169.06M estimate by 0.38%, yet showing a 31.26% increase from the previous year.

Portfolio Pulse from Benzinga Newsdesk

February 22, 2024 | 12:40 pm

Earnings reports for various companies are scheduled for February 22, 2024, covering a wide range of industries. These reports include both earnings per share and revenue forecasts, with some companies expected to report losses.

Portfolio Pulse from Benzinga Insights

February 22, 2024 | 10:27 am

Harmony Biosciences announced that the FDA has granted priority review for its supplemental New Drug Application (sNDA) for WAKIX, aimed at expanding its use. This development could significantly impact Harmony Biosciences' market position and future revenue streams, as priority review can expedite the drug's approval process.

Portfolio Pulse from Benzinga Newsdesk

February 21, 2024 | 1:07 pm

Harmony Biosciences has been granted FDA Orphan Drug Designation for Pitolisant, a significant milestone that could enhance the company's market position and potentially lead to expedited development and approval processes for this drug.

Portfolio Pulse from Benzinga Newsdesk

February 20, 2024 | 1:07 pm

Mizuho analyst Graig Suvannavejh maintains a Buy rating on Harmony Biosciences (NASDAQ:HRMY) and raises the price target from $33 to $42.

Portfolio Pulse from Benzinga Newsdesk

February 16, 2024 | 11:50 pm

Goldman Sachs analyst Corinne Jenkins has maintained a Sell rating on Harmony Biosciences (NASDAQ:HRMY) but increased the price target from $25 to $28.

Portfolio Pulse from Benzinga Newsdesk

January 09, 2024 | 1:14 pm

Harmony Biosciences projects 2024 net product revenue between $700M-$720M and has repurchased $50M in common stock in Q4 2023, totaling $100M for the year. The company plans to continue share repurchases in 2024. Key priorities include growing WAKIX for narcolepsy, advancing the pipeline with several trials, and disciplined capital allocation to maximize shareholder value. The financial data is preliminary and unaudited.

Portfolio Pulse from Benzinga Newsdesk

January 08, 2024 | 1:34 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.